0001055726-23-000005.txt : 20230228 0001055726-23-000005.hdr.sgml : 20230228 20230228174200 ACCESSION NUMBER: 0001055726-23-000005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230226 FILED AS OF DATE: 20230228 DATE AS OF CHANGE: 20230228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIES PETER CENTRAL INDEX KEY: 0001259780 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14888 FILM NUMBER: 23687803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INOVIO PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001055726 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330969592 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584103134 MAIL ADDRESS: STREET 1: 6769 MESA RIDGE RD. CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: INOVIO BIOMEDICAL CORP DATE OF NAME CHANGE: 20050404 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL CORP DATE OF NAME CHANGE: 20011116 FORMER COMPANY: FORMER CONFORMED NAME: GENETRONICS BIOMEDICAL LTD DATE OF NAME CHANGE: 19980213 4 1 wf-form4_167762408938905.xml FORM 4 X0306 4 2023-02-26 0 0001055726 INOVIO PHARMACEUTICALS, INC. INO 0001259780 KIES PETER C/O INOVIO PHARMACEUTICALS, INC. 6769 MESA RIDGE ROAD SAN DIEGO CA 92121 0 1 0 0 CFO Common Stock 2023-02-26 4 M 0 22544 A 201828 D Common Stock 2023-02-26 4 F 0 12928 1.28 D 188900 D Common Stock 2023-02-26 4 M 0 47967 A 236867 D Common Stock 2023-02-26 4 F 0 28195 1.28 D 208672 D Common Stock 4500 I By Spouse Restricted Stock Unit 2023-02-26 4 M 0 22544 0 D Common Stock 22544.0 22544 D Restricted Stock Unit 2023-02-26 4 M 0 47967 0 D Common Stock 47967.0 95933 D Common Stock Option 1.24 2023-02-27 4 A 0 225000 0 A 2023-02-27 2033-02-27 Common Stock 225000.0 225000 D Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 143,900 restricted stock units, vesting as follows: 47,967 shares vested on February 26, 2023; 47,967 shares will vest on February 26, 2024; and 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. The vesting schedule for the 225,000 options is as follows: 56,250 shares vested on February 27, 2023; 56,250 shares will vest on February 26, 2024; 56,250 shares will vest on February 26, 2025; and 56,250 shares will vest on February 26, 2026. Peter Kies 2023-02-28